Vaccination induces HIV broadly neutralizing antibody precursors in humans.
Science
; 378(6623): eadd6502, 2022 12 02.
Article
in En
| MEDLINE
| ID: mdl-36454825
ABSTRACT
Broadly neutralizing antibodies (bnAbs) can protect against HIV infection but have not been induced by human vaccination. A key barrier to bnAb induction is vaccine priming of rare bnAb-precursor B cells. In a randomized, double-blind, placebo-controlled phase 1 clinical trial, the HIV vaccine-priming candidate eOD-GT8 60mer adjuvanted with AS01B had a favorable safety profile and induced VRC01-class bnAb precursors in 97% of vaccine recipients with median frequencies reaching 0.1% among immunoglobulin G B cells in blood. bnAb precursors shared properties with bnAbs and gained somatic hypermutation and affinity with the boost. The results establish clinical proof of concept for germline-targeting vaccine priming, support development of boosting regimens to induce bnAbs, and encourage application of the germline-targeting strategy to other targets in HIV and other pathogens.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
HIV Antibodies
/
HIV Infections
/
AIDS Vaccines
/
Immunoglobulin Heavy Chains
/
Immunoglobulin Light Chains
/
Broadly Neutralizing Antibodies
/
Germ Cells
Type of study:
Clinical_trials
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
En
Journal:
Science
Year:
2022
Document type:
Article
Affiliation country:
Estados Unidos